Clinical Trials Logo

Citation(s)

Immunogenicity and Safety of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342) When Administered to Healthy Adults Aged 21 to 40 Years.

Details for clinical trial NCT00600782